España
es posible, quizas sepan que habran tenido ya para entonces meeting con la FDA y que pudieran tener algun guidance al respecto. En cualquier caso y por mi parte, aqui primero ver para creer y segun a que precio para volver a entrar. Que el ER en NVAX siempre trae tela ...
NVAX
si, ya vi que la desviacion era del 3% ... el mercado esta asi, castigando sin compasion.
el nivel pivotal a no rebasar es 127$
ILMN
danip, no la conocía, me la acabo de instalar porque tampoco usaba alertas. gracias por el tip
y veo que la app tiene muchos datos de rapida consulta de AT. Gracias
RDUS
Por lo que leo en ST, y viendo el premarket, parece que se re-avivan los rumores del BO de RDUS por Shire.
Shire close to deal for Radius Health
http://www.seekingalpha.com/news/3213304
HZNP
Otra que recorta expectativas de Q3 y de todo el año
The Company is revising its full-year 2016 adjusted EBITDA guidance range as the result of expected net sales at the low end of its non-GAAP adjusted net sales guidance range and anticipated higher investment spending in the fourth quarter of 2016 and now expects adjusted EBITDA to be in the range of $450 to $460 million (prior range was $495 to $510 million).
http://ir.horizon-pharma.com/secfiling.cfm?filingID=1193125-16-734829&CIK=1492426
De momento -5% en PM tras conocerse la noticia
pues esta no se toma estas cosas nada bien ...
La MM200 en 17,89 ... que ademas es zona de soporte inferior del canal. Ese nivel nos lo va a decir todo ...
HZNP
ARNA
Arena Pharmaceuticals Announces Acceptance of Late Breaking Etrasimod Abstract at the United European Gastroenterology Week (UEGW) Meeting
Dr. Laurent Peyrin-Biroulet will present etrasimod S1P receptor profile data at the United European Gastroenterology Week (UEGW) Meeting on Tuesday, October 18 at 6:15am ET. The meeting is taking place October 15-19 in Vienna, Austria. The data will also be published in the December issue of United European Gastroenterology Journal, a peer-reviewed medical journal providing coverage of both translational as well as clinical studies from all fields of gastroenterology.
The following abstract will be presented:
Lecture: LB20 - RECEPTOR PROFILE AND EFFICACY OF ETRASIMOD (APD334), AN ORAL, NEXT-GENERATION SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATOR IN DEVELOPMENT FOR ULCERATIVE COLITIS
Session: 807 - Improving therapy in IBD
Session Type: Late Breaking Abstracts
Date: Tuesday, October 18, 2016